

Cefotaxime Sodium**CEF****SECTION 1 Identification of the substance/mixture and of the company/undertaking****1.1. Product identifier**

Identification of the product	: Raw material
Product code	: CEFO001, CEFO005, CEFO025
Trade name	: Cefotaxime Sodium
CAS number	: 64485-93-4
EC No	: 264-915-9
Molecular Formula	: C16H16N5NaO7S2
Molecular Weight	: 477.45 g/mol

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use	: For research purposes only
------------	------------------------------

1.3. Details of the supplier of the safety data sheet

Company identification	Formedium Ltd. King's Lynn, England, PE31 6DJ Tel: +44(0)1485 609069 Web: www.Formedium.com E-mail: info@formedium.com
-------------------------------	--

1.4. Emergency telephone number

Emergency phone nr	: Tel: +44(0)1485 609069 (local time : 9.00 to 17.00) NHS Direct 111 (UK, 24 hours), 112 (EU, 24 Hours)
---------------------------	--

SECTION 2 Hazards identification**2.1. Classification of the substance or mixture****Regulation (EC) No. 1272 / 2008****Hazard categories:**

Respiratory Sensitization : Category 1, H334

Skin Sensitization : Category 1, H317

Hazard Statements:

H317 - May cause an allergic skin reaction.

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2. Label elements**Regulation (EC) No. 1272/2008****Hazard components for labelling**

Sodium [6r-[6α,7β(z)]]-3-(acetoxymethyl)-7-[(2-aminothiazol-4-yl)(methoxyimino)acetamido]-8-oxo5-thia-1-azabicyclo[4.2.0]oct-2-ene

Cefotaxime Sodium**CEF****SECTION 2 Hazards identification (continued)****Labelling Regulation EC 1272/2008 (CLP)**

- Hazard pictograms code : GHS08



: Danger

- Signal word

- Hazard statements

H317 May cause an allergic skin reaction.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

- Precautionary statements

P261 Avoid breathing dust.

P280 Wear protective gloves.

P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER or doctor/ physician.

2.3. Other hazards

None under normal conditions.

SECTION 3 Composition/information on ingredients**3.1. Substances****Chemical characterization**

Formula : C₁₆H₁₆N₅NaO₇S₂

Molecular Weight : 477.45 g/mol

CAS No : 64485-93-4

EC No : 264-915-9

Component :

Sodium [6r-6a,7β(z)]-3-(acetoxymethyl)-7-[(2-aminothiazol-4-yl)(methoxyimino)acetamido]-8-oxo5-thia-1-azabicyclo[4.2.0]oct-2-ene

SECTION 4 First aid measures**4.1. Description of first aid measures**

General Information: Consult a physician. Show this safety data sheet to the doctor in attendance.

Inhalation: If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

Skin contact: Wash off with soap and plenty of water. Consult a physician.

Eye contact: Flush eyes with water as a precaution.

Ingestion: Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

4.2. Most important symptoms and effects, both acute and delayed

The most important known symptoms and effects are as described in the labelling (see section 2.2) and / or in section 11.

4.3. Indication of any immediate medical attention and special treatment needed

No information available.

Cefotaxime Sodium**CEF****SECTION 5 Fire-fighting measures****5.1. Extinguishing media**

Suitable extinguishing media : Water spray.
Alcohol resistant foam.
Dry extinguishing powder.
Carbon Dioxide (CO2).

5.2 Special hazards arising from the substance or mixture

No data available.

5.3. Advice for firefighters

Wear self-contained breathing apparatus for fire fighting if necessary.

5.4. Additional information

No data available.

SECTION 6 Accidental release measures**6.1. Personal precautions, protective equipment and emergency procedures**

Use personal protective equipment. Ensure adequate ventilation. Avoid dust formation. Avoid breathing vapours, mist or gas. Avoid breathing dust. Evacuate personnel to safe areas.
For personal protection see section 8.

6.2. Environmental precautions

Do not let product enter drains or surface water.

6.3. Methods and material for containment and cleaning up

Pick up and arrange disposal without creating dust. Sweep up and shovel.
Keep in suitable, closed containers for disposal.

6.4. Reference to other sections

For disposal : see section 13

SECTION 7 Handling and storage**7.1. Precautions for safe handling****Advice on safe handling**

Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.

7.2. Conditions for safe storage, including any incompatibilities**Requirements for storage rooms and vessels**

Store in a cool place.

Keep container tightly closed in a dry and well ventilated place.

Recommended storage temperature

2 – 8 Deg C

7.3. Specific end use(s)

For research purposes only.

Cefotaxime Sodium**CEF****SECTION 8 Exposure controls/personal protection****8.1. Control parameters****Components with workplace control parameters**

Contains no substances with occupational exposure limit values.

8.2. Exposure controls**Appropriate engineering controls**

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of the work day.

Personal protective equipment**Eye / face protection**

Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed.

Skin protection

Wear suitable protective clothing.

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.

Body Protection

Complete suit protecting against chemicals. The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Respiratory protection

For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

SECTION 9 Physical and chemical properties**9.1. Information on basic physical and chemical properties**

Physical state	: Powder
Colour	: beige
Odour	: no data available
Odour threshold	: no data available
pH value (at 20°C)	: no data available
Melting point / freezing point	: no data available
Initial boiling point and boiling range	: no data available
Flash point	: no data available
Flammability (Solid/Gas)	: not determined
Upper / Lower flammability or explosive limits	: not determined
Vapour pressure	: not determined
Vapour density	: no data available

Cefotaxime Sodium**CEF****SECTION 9 Physical and chemical properties (continued)**

Relative density	: not determined
Water solubility	: ca 50 g/l
Partition coefficient	: not determined
Decomposition temperature	: not determined
Partition coefficient	
n-octanol / water	: not determined
Auto-ignition temperature	: no data available
Viscosity	: no data available
Explosive properties	: no data available
Oxidizing properties	: no data available

9.2. Other information

No data available

SECTION 10 Stability and reactivity**10.1. Reactivity**

No data available.

10.2. Chemical stability

The product is chemically stable under recommended storage conditions (2 – 8 Deg C).

10.3. Possibility of hazardous reactions

No data available.

10.4. Conditions to avoid

No data available.

10.5. Incompatible materials

Strong oxidizing agents.

10.6. Hazardous decomposition products

Hazardous decomposition products formed under fire conditions – Carbon oxides, Nitrogen oxides (NOx), Sulphur oxides, Sodium oxides.

Other decomposition products – No data available.

In the event of fire : see section 5.

Cefotaxime Sodium**CEF****SECTION 11 Toxicological information****11.1. Information on toxicological effects****Acute toxicity**

LD50 Oral – rat -> 20,000 mg/kg

Remarks: Behavioural Food intake (animal). Behavioural: Ataxia. Lungs, Thorax or Respiration: Other changes.

Skin corrosion / irritation

: No data available.

Serious eye damage / eye irritation

: No data available.

Respiratory or skin sensitization

: May cause allergic respiratory and skin reactions.

Germ cell mutagenicity

: No data available.

Carcinogenicity

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Reproductive toxicity

Developmental Toxicity – Rabbit – Intravenous

Effects on Embryo or Foetus : Foetal death.

Specific target organ toxicity – single exposure

No data available.

Specific target organ toxicity –repeated exposure

No data available.

Additional Information

RTECS: X10250000

Because of the similarity in structure of the penicillin's and cephalosporins, those who are allergic to one class of agents may manifest cross-allergenicity when a member of the other class is encountered.

Gastrointestinal disturbance, increased liver enzymes.

To the best of our knowledge, the chemical, physical and toxicological properties have not been thoroughly investigated.

11.2. Additional Information**Endocrine disrupting properties :**

The Substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 12 Ecological information**12.1. Toxicity**

No data available.

12.2. Persistence - degradability

This product has not been tested. No data available.

12.3. Bioaccumulative potential

No data available.

12.4. Mobility in soil

No data available.

12.5. Results of PBT and vPvB assessment

PBT / vPvB assessment not available as chemical safety assessment not required / not conducted.

12.6. Other adverse effects

No data available.

12.7. Endocrine disrupting properties

The Substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Cefotaxime Sodium**CEF****SECTION 13 Disposal considerations****13.1. Waste treatment methods****Product**

Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging

Handle contaminated packages in the same way as the substance itself.

SECTION 14 Transport information**14.1. UN Number**

Not applicable

General information : Not classified as dangerous in the meaning of transport regulations

14.2. Proper shipping name

Not applicable

14.3. Transport Hazard Classification

Not applicable

14.4. Packing Group

Not applicable

14.5. Environmental hazards

Not applicable

14.6. Special precautions for user

Not applicable

14.7. Transport in bulk according to Annex II of Marpol and the IBC Code

Not applicable

Cefotaxime Sodium**CEF****SECTION 15 Regulatory information****15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture**

This safety datasheet complies with the requirements of Regulation (EC) No. 2015/830

15.2. Chemical safety assessment

For this substance a chemical safety assessment has not been carried out.

SECTION 16 Other information**Further information :**

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Formedium Ltd. shall not be held liable for any damage resulting from handling or from contact with the above product.

Complete SDS revision**End of document**